{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:40:46Z","timestamp":1786984846178,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T00:00:00Z","timestamp":1636675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","award":["16155"],"award-info":[{"award-number":["16155"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.atherosclerosis.2021.11.011","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:15:31Z","timestamp":1636668931000},"page":"12-19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization"],"prefix":"10.1016","volume":"339","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9554-7292","authenticated-orcid":false,"given":"Thomas","family":"Gremmel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1746-4819","authenticated-orcid":false,"given":"Alan D.","family":"Michelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2462-4515","authenticated-orcid":false,"given":"Patricia P.","family":"Wadowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Pultar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Weikert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Tscharre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Panzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Andrew L.","family":"Frelinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nrd2957","article-title":"Antiplatelet therapies for the treatment of cardiovascular disease","volume":"9","author":"Michelson","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib2","first-page":"1","article-title":"Oral antiplatelet agents in cardiovascular disease","volume":"48","author":"Pultar","year":"2018","journal-title":"Vasa"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.5551\/jat.24935","article-title":"Impact of sex and gender on the efficacy of antiplatelet therapy: the female perspective","volume":"22","author":"Basili","year":"2015","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib5","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.atherosclerosis.2014.10.095","article-title":"Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis","volume":"237","author":"Gremmel","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0035-1564835","article-title":"Platelet physiology","volume":"42","author":"Gremmel","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI6042","article-title":"Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin","volume":"103","author":"Kahn","year":"1999","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/rth2.12213","article-title":"Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors","volume":"3","author":"Wadowski","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/ATVBAHA.120.315033","article-title":"Sex-specific platelet activation through protease-activated receptors reverses in myocardial infarction","volume":"41","author":"Soo Kim","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib10","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3109\/09537104.2015.1095876","article-title":"In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization","volume":"27","author":"Gremmel","year":"2016","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib11","doi-asserted-by":"crossref","first-page":"20741","DOI":"10.1016\/S0021-9258(19)36844-9","article-title":"Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation","volume":"268","author":"Coller","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib12","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1080\/09537104.2018.1478073","article-title":"Using flow cytometry to monitor glycoprotein IIb-IIIa activation","volume":"29","author":"Frelinger","year":"2018","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib13","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.thromres.2011.11.019","article-title":"Influence of cytochrome 2C19 allelic variants on on-treatment platelet reactivity evaluated by five different platelet function tests","volume":"129","author":"Gremmel","year":"2012","journal-title":"Thromb. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib14","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.atherosclerosis.2009.05.037","article-title":"The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity","volume":"207","author":"Gremmel","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2013.10.027","article-title":"Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty","volume":"232","author":"Gremmel","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib16","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.trsl.2012.12.015","article-title":"Obesity is associated with poor response to clopidogrel and an increased susceptibility to protease activated receptor-1 mediated platelet activation","volume":"161","author":"Gremmel","year":"2013","journal-title":"Transl. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1600-0609.1985.tb00804.x","article-title":"Platelet count and platelet size in males and females","volume":"25","author":"Bain","year":"1985","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1084\/jem.190.6.803","article-title":"The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin","volume":"190","author":"Romo","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1160\/TH14-08-0690","article-title":"Impact of variables of the P-selectin - P-selectin glycoprotein ligand-1 axis on leukocyte-platelet interactions in cardiovascular disease","volume":"113","author":"Gremmel","year":"2015","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0129666","article-title":"Comparison of aggregometry with flow cytometry for the assessment of agonists -induced platelet reactivity in patients on dual antiplatelet therapy","volume":"10","author":"Gremmel","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib21","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09537104.2010.543963","article-title":"Comparison of methods to evaluate aspirin-mediated platelet inhibition after percutaneous intervention with stent implantation","volume":"22","author":"Gremmel","year":"2011","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib22","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1111\/j.1538-7836.2007.02656.x","article-title":"Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients","volume":"5","author":"Paniccia","year":"2007","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib23","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12231","article-title":"Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC\/isth","author":"Cattaneo","year":"2013","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib24","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1160\/TH06-05-0242","article-title":"Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood","volume":"96","author":"Toth","year":"2006","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib25","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib26","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/09537104.2010.493587","article-title":"Is TRAP-6 suitable as a positive control for platelet reactivity when assessing response to clopidogrel?","volume":"21","author":"Gremmel","year":"2010","journal-title":"Platelets"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib27","first-page":"474","article-title":"In vivo and protease-activated receptor-1-mediated platelet activation but not response to antiplatelet therapy predict two-year outcomes after peripheral angioplasty with stent implantation","volume":"111","author":"Gremmel","year":"2014","journal-title":"Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib28","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events","volume":"366","author":"Morrow","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib29","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa1109719","article-title":"Thrombin-receptor antagonist vorapaxar in acute coronary syndromes","volume":"366","author":"Tricoci","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1161\/CIRCRESAHA.119.315099","article-title":"Rivaroxaban reduces arterial thrombosis by inhibition of FXa-driven platelet activation via protease activated receptor-1","volume":"126","author":"Petzold","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/jth.13595","article-title":"Dabigatran enhances platelet reactivity and platelet thrombin receptor expression in patients with atrial fibrillation","volume":"15","author":"Achilles","year":"2017","journal-title":"J. Thromb. Haemostasis"},{"key":"10.1016\/j.atherosclerosis.2021.11.011_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jacc.2015.05.012","article-title":"The multifaceted clinical readouts of platelet inhibition by low-dose aspirin","volume":"66","author":"Patrono","year":"2015","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915021014386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:26:22Z","timestamp":1762187182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915021014386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":32,"alternative-id":["S0021915021014386"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.011","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}